Ralf Kuriyel - Repligen Senior Vice President - Research & Development
| RGEN Stock | USD 167.86 3.42 2.00% |
President
Mr. Ralf Kuriyel joined Repligen in October 2016 as our Senior Vice President, Research and Development, where he oversees the Companys research and development efforts. Mr. Kuriyel was previously with Pall Life Sciences, where he served as Vice President of RD, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications RD at Pall from November 2011 to November 2014 since 2016.
| Age | 66 |
| Tenure | 8 years |
| Address | Building 1, Waltham, MA, United States, 02453 |
| Phone | 781 250 0111 |
| Web | https://www.repligen.com |
Latest Insider Transactions
Kuriyel received a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and an M.S. in Chemical Engineering from Rensselaer Polytechnic Institute.Ralf Kuriyel Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ralf Kuriyel against Repligen stock is an integral part of due diligence when investing in Repligen. Ralf Kuriyel insider activity provides valuable insight into whether Repligen is net buyers or sellers over its current business cycle. Note, Repligen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Repligen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ralf Kuriyel over a month ago Acquisition by Ralf Kuriyel of 1271 shares of Repligen at 86.1 subject to Rule 16b-3 |
Repligen Management Efficiency
The company has return on total asset (ROA) of 0.0131 % which means that it generated a profit of $0.0131 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0214 %, meaning that it created $0.0214 on every $100 dollars invested by stockholders. Repligen's management efficiency ratios could be used to measure how well Repligen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.02. At this time, Repligen's Intangible Assets are very stable compared to the past year. As of the 25th of April 2024, Net Tangible Assets is likely to grow to about 847.1 M, while Deferred Long Term Asset Charges is likely to drop about 2.2 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Karen McGinnis | Illumina | 50 | |
| Erlinger Sherbet | IQVIA Holdings | 51 | |
| Richard III | IQVIA Holdings | 61 | |
| Richard Staub | IQVIA Holdings | 54 | |
| Nilton Paletta | IQVIA Holdings | N/A | |
| Kevin Knightly | IQVIA Holdings | 63 | |
| Paula Dowdy | Illumina | N/A | |
| Jacqueline Studer | IDEXX Laboratories | 58 | |
| Ronald Bruehlman | IQVIA Holdings | 63 | |
| Michael Lane | IDEXX Laboratories | 55 | |
| Mark Brecher | Laboratory of | 57 | |
| Mostafa Ronaghi | Illumina | 49 | |
| Charles Dadswell | Illumina | 65 | |
| Samuel Eberts | Laboratory of | 57 | |
| Nicholas Naclerio | Illumina | 53 | |
| Walter Staub | IQVIA Holdings | 57 | |
| Lance Berberian | Laboratory of | 61 | |
| Eric Sherbet | IQVIA Holdings | 60 | |
| Wendy Stewart | IQVIA Holdings | N/A | |
| Marcel Roche | Guardant Health | N/A | |
| Sanjay Chikarmane | Illumina | N/A | |
Management Performance
| Return On Equity | 0.0214 | ||||
| Return On Asset | 0.0131 |
Repligen Leadership Team
Elected by the shareholders, the Repligen's board of directors comprises two types of representatives: Repligen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Repligen. The board's role is to monitor Repligen's management team and ensure that shareholders' interests are well served. Repligen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Repligen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Ryan, Independent Director | ||
| Christine Gebski, Senior Chromatography | ||
| Kimberly Cornwell, General Counsel | ||
| James Bylund, Chief Officer | ||
| Howard Benjamin, VP of Bus. Devel. | ||
| Tony Hunt, COO, Treasurer | ||
| Rachel Goodrich, VP Marketing | ||
| Neil Whitfield, Vice Sales | ||
| Alexander Rich, Independent Chairman Emeritus of the Board | ||
| Glenn Muir, Director | ||
| Keith Robinson, Chief Officer | ||
| Sondra Newman, Global Relations | ||
| Craig Harrison, VP Analytics | ||
| Dianne Heiler, Senior Sustainability | ||
| Kola Otitoju, Senior Development | ||
| James Rusche, Sr. VP of RandD | ||
| Stephen Tingley, VP Sales | ||
| Jaime Humara, Senior Marketing | ||
| Jon Snodgres, Chief Officer | ||
| Olivier Loeillot, President Officer | ||
| Ralf Kuriyel, Senior Vice President - Research & Development | ||
| Leslie Galvin, Global Resources | ||
| Mark Salerno, VP Analytics | ||
| Alfred Goldberg, Independent Director | ||
| Karen Dawes, Independent Chairperson of the Board | ||
| Jason Garland, Chief Officer | ||
| Glenn Cooper, Independent Director | ||
| John Cox, Director | ||
| Nicolas Barthelemy, Director | ||
| Anthony Hunt, President CEO, Director | ||
| Michael Griffith, Independent Director |
Repligen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Repligen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0214 | ||||
| Return On Asset | 0.0131 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 9.32 B | ||||
| Shares Outstanding | 55.84 M | ||||
| Shares Owned By Insiders | 6.59 % | ||||
| Shares Owned By Institutions | 93.41 % | ||||
| Number Of Shares Shorted | 4.59 M | ||||
| Price To Earning | 154.58 X |
Repligen Investors Sentiment
The influence of Repligen's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Repligen. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Repligen's public news can be used to forecast risks associated with an investment in Repligen. The trend in average sentiment can be used to explain how an investor holding Repligen can time the market purely based on public headlines and social activities around Repligen. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Repligen's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Repligen's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Repligen's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Repligen.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Repligen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Repligen's short interest history, or implied volatility extrapolated from Repligen options trading.
Currently Active Assets on Macroaxis
When determining whether Repligen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Repligen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Repligen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Repligen Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.Note that the Repligen information on this page should be used as a complementary analysis to other Repligen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Repligen Stock analysis
When running Repligen's price analysis, check to measure Repligen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repligen is operating at the current time. Most of Repligen's value examination focuses on studying past and present price action to predict the probability of Repligen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repligen's price. Additionally, you may evaluate how the addition of Repligen to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Repligen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.55) | Earnings Share 0.74 | Revenue Per Share 11.464 | Quarterly Revenue Growth (0.17) | Return On Assets 0.0131 |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.